Supernus, Inc. (SUPN)
SUPNNASDAQ-GSBiotechnology: Pharmaceutical Preparations
$27.99
+0.3650 (+1.32%) today
Regular session, Nov 10, 10:06 AM ET
- Market cap
- $3.30bn
- P/E
- 6.6
- EPS, last 4 quarters
- $4.25
- Dividend yield
- –
- Day range
- $27.33 to $28.15
- 52-week range
- $25.92 to $42.81
- Average volume
- 2.77m
- Previous close
- $27.62
Analysts
5 coveringBuy4 buy, 1 hold, 0 sell
Targets a year out average $52.60, +88.0% from here
Earnings
next estimate $0.9700Next report
Dec 2025
+26.1%
Mar 2026
+50.0%
Jun 2026
+18.6%
Sep 2026
+41.9%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $211.57m | $207.71m | $219.06m | $226.77m |
| Gross profit | $188.56m | $184.31m | $185.39m | $199.75m |
| Operating income | -$3.94m | -$8.33m | -$57.96m | $21.18m |
| Net income | -$4.11m | -$2.29m | -$58.37m | $20.91m |
Last four quarters: revenue $865.11m, margin -5.1%, free cash flow –
News
8 latest- Why Indivior Pharmaceuticals Stock Topped the Market TodayThe Motley Fool · Nov 2, 2026
- Indivior PLC Reports Third Quarter 2026 Financial ResultsFintel · Oct 29, 2026
- Indivior Pharmaceuticals Inc. (INDV) Beats Q3 Earnings and Revenue EstimatesZacks · Oct 29, 2026
- Indivior Plc. Announces Climb In Q3 Income RTTNews · Oct 29, 2026
- After Hours Most Active for Oct 12, 2026 : NU, CMCSA, INDV, CTRI, NVDA, SNAP, TRVI, TJX, GOOGL, AMZN, CBZ, NOKNASDAQ.com · Oct 12, 2026
- After Hours Most Active for Oct 9, 2026 : FTXR, NVDA, BKD, GRAB, TRVI, URGN, INDV, LUV, WFC, ESI, OSG, BACNASDAQ.com · Oct 9, 2026
- Here's Why Indivior Pharmaceuticals Inc. (INDV) is a Strong Growth StockZacks · Sep 24, 2026
- Indivior Pharmaceuticals Declares $8.13 Special Cash Dividend Contingent On Pending Merger; Stock Up RTTNews · Sep 17, 2026
The company
Supernus, Inc. is a leading, diversified biopharmaceutical company focused on developing and commercializing treatments for patients living with central nervous system (CNS) diseases. Our commercial portfolio includes approved treatments designed to support individuals navigating opioid use disorder (OUD), attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's disease (PD) for those receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. Backed by strong commercial capabilities and scientific expertise, we are committed to continuous innovation, advancing a robust pipeline of novel product candidates to deliver meaningful outcomes for CNS patients.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GS
- Region
- Europe
- Website
- indivior.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.